[

bharat biotech

]
PAGE 2
A medic checks the temperature of ice packs in a deep freezer at a Covid-19 vaccine storage facility in Ahmedabad.(PTI)

Covid-19 vaccine: Data India seeks from Serum Institute, Bharat Biotech; Canada’s approval to Pfizer vaccine shot | 10 points

By hindustantimes.com | Edited by Poulomi Ghosh | Hindustan Times, New Delhi
UPDATED ON DEC 10, 2020 08:33 AM IST
Bharat Biotech will have to submit the safety and efficacy data from the ongoing phase 3 clinical trial in the country.
Close
At a meeting to review the emergency authorisation of vaccine makers, the CDSCO’s subject expert committee (SEC) reviewed the authorisation sought by Serum Institute and Bharat Biotech but did not consider a similar application from Pfizer-BioNTech because their US experts could not attend the meeting.(File photo for representation)
At a meeting to review the emergency authorisation of vaccine makers, the CDSCO’s subject expert committee (SEC) reviewed the authorisation sought by Serum Institute and Bharat Biotech but did not consider a similar application from Pfizer-BioNTech because their US experts could not attend the meeting.(File photo for representation)

Covid-19: Expert panel seeks more data from Serum Institute of India, Bharat Biotech

By Agencies | New Delhi
UPDATED ON DEC 09, 2020 10:15 PM IST
The expert committee of the Central Drugs Standard Control Organisation (CDSCO) on Wednesday sought additional safety and efficacy data from the Serum Institute of India and Bharat Biotech for their coronavirus disease (Covid-19) vaccine, after deliberating upon their applications seeking authorisation for the shots.
Close
Foreign envoys at Bharat Biotech’s facility in Hyderabad on Wednesday.(HT PHOTO)
Foreign envoys at Bharat Biotech’s facility in Hyderabad on Wednesday.(HT PHOTO)

India playing key role against Covid-19, says Bharat Biotech as 64 envoys visit facility

By Srinivasa Rao Apparasu | Hindustan Times, Hyderabad
UPDATED ON DEC 09, 2020 07:01 PM IST
Bharat Biotech said the envoys appreciated its work of national and global public health significance, through several months to establish a long-lasting efficacious vaccine to combat the extraordinary Covid-19 pandemic
Close
A medic checks the temperature of ice packs in a deep freezer at a Covid-19 vaccine storage facility in Ahmedabad.(PTI)
A medic checks the temperature of ice packs in a deep freezer at a Covid-19 vaccine storage facility in Ahmedabad.(PTI)

Covid-19 vaccine drive: Centre to send additional storage equipment to states from tomorrow

By hindustantimes.com | Edited by Poulomi Ghosh | Hindustan Times, New Delhi
UPDATED ON DEC 09, 2020 06:02 PM IST
The present cold chain system consists of 85,634 equipment for storage of vaccine at about 28,947 cold chain points across the country.
Close
A medic administers Covaxin to a health worker during its trials at the Gujarat Medical Education & Research Society in Ahmedabad.(PTI)
A medic administers Covaxin to a health worker during its trials at the Gujarat Medical Education & Research Society in Ahmedabad.(PTI)

Covid-19 vaccine: Applications of Pfizer, Bharat Biotech and Serum Institute to be reviewed today

By hindustantimes.com | Edited by Poulomi Ghosh | Hindustan Times, New Delhi
UPDATED ON DEC 09, 2020 09:57 AM IST
The experts will go through the voluminous trial data of the vaccine candidates and once they are satisfied with the risk-benefit ratio, they will give the go-ahead.
Close
FILE PHOTO: An employee in personal protective equipment (PPE) removes vials of AstraZeneca's COVISHIELD, coronavirus disease (COVID-19) vaccine from a visual inspection machine inside a lab at Serum Institute of India, Pune, India, November 30, 2020. REUTERS/Francis Mascarenhas/File Photo(REUTERS)
FILE PHOTO: An employee in personal protective equipment (PPE) removes vials of AstraZeneca's COVISHIELD, coronavirus disease (COVID-19) vaccine from a visual inspection machine inside a lab at Serum Institute of India, Pune, India, November 30, 2020. REUTERS/Francis Mascarenhas/File Photo(REUTERS)

Foreign ministry to fly over 60 foreign envoys to Hyderabad for Covid vaccine briefing

By Shishir Gupta | Hindustan Times, New Delhi
UPDATED ON DEC 08, 2020 07:28 PM IST
The diplomats will be taken to the Hyderabad-based Bharat Biotech and Biological E for an interaction with scientists on the Covid-19 vaccine
Close
Vials labelled "COVID-19 Coronavirus Vaccine" are placed on dry ice in this illustration taken, December 4, 2020. REUTERS/Dado Ruvic/Illustration
Vials labelled "COVID-19 Coronavirus Vaccine" are placed on dry ice in this illustration taken, December 4, 2020. REUTERS/Dado Ruvic/Illustration

Pfizer, Serum Institute and Bharat Biotech apply for EUA in India: Here’s what might happen next

By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON DEC 08, 2020 02:27 PM IST
America’s Pfizer was the first firm to apply for EUA in India. Serum Institute and Bharat Biotech, both Indian firms, followed next.
Close
FILE PHOTO: A logo of Pfizer is seen at the entrance to the Pfizer factory in Puurs, Belgium Dec. 3, 2020. REUTERS/Yves Herman/File Photo/File Photo(REUTERS)
FILE PHOTO: A logo of Pfizer is seen at the entrance to the Pfizer factory in Puurs, Belgium Dec. 3, 2020. REUTERS/Yves Herman/File Photo/File Photo(REUTERS)

Covid-19 vaccine update: UK to begin Pfizer vaccinations, Bharat Biotech seeks nod for emergency use in India

By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON DEC 08, 2020 08:07 AM IST
South Korea’s government has said it has signed deals with four firms-AstraZeneca, Pfizer, Moderna and Johnson & Johnson-to vaccinate a total of 44 million people.
Close
A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed Pfizer logo.(Reuters File Photo)
A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed Pfizer logo.(Reuters File Photo)

Review of Covid vaccine applications of Pfizer, SII, Bharat Biotech tomorrow: Report

By Press Trust of India | Posted by Kanishka Sarkar | New Delhi
UPDATED ON DEC 08, 2020 06:16 AM IST
The decision was taken late on Monday evening after the Hyderabad-based Bharat Biotech became the third pharmaceutical firm to apply to the Drugs Controller General of India (DCGI) for emergency use authorisation for its indigenously developed Covid-19 vaccine Covaxin.
Close
The private pharmaceutical company based in the southern city of Hyderabad is developing a vaccine called Covaxin that it plans to launch by the second quarter of 2021.(PTI (Representative Image))
The private pharmaceutical company based in the southern city of Hyderabad is developing a vaccine called Covaxin that it plans to launch by the second quarter of 2021.(PTI (Representative Image))

Bharat Biotech seeks emergency use authorization for Covid-19 vaccine

By Press Trust of India | Posted by Nilavro Ghosh | New Delhi
UPDATED ON DEC 07, 2020 10:57 PM IST
The company filed its application with the Drugs Controller General of India earlier on Monday, the source said.
Close
Scientists at work at a Covaxin trial site of ICMR-NICED during phase-III regulatory trial of the Covid-19 vaccine candidate, in Kolkata.(PTI)
Scientists at work at a Covaxin trial site of ICMR-NICED during phase-III regulatory trial of the Covid-19 vaccine candidate, in Kolkata.(PTI)

Safety primary criteria in vaccine development: Covaxin maker Bharat Biotech after Anil Vij contracts Covid-19

By hindustantimes.com| Edited by Mallika Soni | Hindustan Times, New Delhi
UPDATED ON DEC 05, 2020 06:47 PM IST
Bharat Biotech recently announced the beginning of Phase 3 trials of Covaxin among 26,000 volunteers across 25 sites in partnership with the Indian Council of Medical Research (ICMR). It is the largest clinical trial conducted for a Covid-19 vaccine in India
Close
FILE PHOTO: Bharat Biotech’s Covaxin is India’s first indigenous Covid-19 vaccine (REUTERS/File Photo)
FILE PHOTO: Bharat Biotech’s Covaxin is India’s first indigenous Covid-19 vaccine (REUTERS/File Photo)

Bharat Biotech’s Covaxin: List of states which have started phase 3 trials of Covid-19 vaccine

By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON DEC 02, 2020 04:04 PM IST
On November 16, Bharat Biotech had announced the commencement of the third phase trials of Covaxin, which it has developed in collaboration with the Indian Council of Medical Research (ICMR).
Close
PM Modi at the Bharat Biotech facility in Hyderabad.(@narendramodi/Twitter)
PM Modi at the Bharat Biotech facility in Hyderabad.(@narendramodi/Twitter)

PM congratulates scientists at Bharat Biotech for progress in Covaxin trials

By Srinivasa Rao Apparasu | Hindustan Times, Hyderabad
UPDATED ON NOV 28, 2020 06:43 PM IST
The phase 3 trial is being conducted across India on 26,000 participants.
Close
People wait during the administration of Covaxin, a government-backed experimental Covid-19 vaccine, during its human trials, at the Gujarat Medical Education & Research Society in Ahmedabad, on Thursday.(PTI Photo)
People wait during the administration of Covaxin, a government-backed experimental Covid-19 vaccine, during its human trials, at the Gujarat Medical Education & Research Society in Ahmedabad, on Thursday.(PTI Photo)

No complaint from volunteers given Bharat Biotech’s Covaxin: Ahmedabad doctor

By hindustantimes.com | Edited by Meenakshi Ray | Hindustan Times, New Delhi
UPDATED ON NOV 27, 2020 05:41 PM IST
Dr Parul Bhatt, the medical superintendent of the Sola Civil Hospital in Gujarat’s Ahmedabad, said the second dose of Bharat Biotech International Limited’s Covid-19 vaccine will now be given after 28 days.
Close
A health worker prepares a needle to inject the 'Gam-COVID-Vac', also known as 'Sputnik V', COVID-19 vaccine, developed by the Gamaleya National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), during a trial at the City Clinic #2 in Moscow, Russia, on Thursday, Nov. 26, 2020 (Photographer: Andrey Rudakov/Bloomberg)(Bloomberg)
A health worker prepares a needle to inject the 'Gam-COVID-Vac', also known as 'Sputnik V', COVID-19 vaccine, developed by the Gamaleya National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), during a trial at the City Clinic #2 in Moscow, Russia, on Thursday, Nov. 26, 2020 (Photographer: Andrey Rudakov/Bloomberg)(Bloomberg)

Covid-19 vaccine update: PM Modi to visit vaccine development centres, AstraZeneca eyes second global trial

By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 27, 2020 07:44 AM IST
Russia has suggested its vaccine candidate, Sputnik V, can be combined with AstraZeneca’s candidate to boost latter’s efficacy. Canada, meanwhile, could approve Pfizer Inc’s vaccine candidate in December.
Close
FILE PHOTO: A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken, October 30, 2020. REUTERS/Dado Ruvic/File Photo(REUTERS)
FILE PHOTO: A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken, October 30, 2020. REUTERS/Dado Ruvic/File Photo(REUTERS)

Covid-19 vaccine update: COVAXIN trials in Gujarat, AstraZeneca admits ‘error’

By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 26, 2020 05:06 PM IST
China National Biotec Group Company has applied to Chinese health regulators to bring its candidate to the market. In Brazil, meanwhile, America’s Pfizer Inc has started the process to get its candidate registered.
Close
FILE PHOTO: Trailers are shown in a city parking lot after a Phase 3 trial location of Johnson & Johnson's Janssen (COVID-19) vaccine candidate was announced in National City during the outbreak of the coronavirus disease (COVID-19) in National City, California, U.S., October 13, 2020. REUTERS/Mike Blake(REUTERS)
FILE PHOTO: Trailers are shown in a city parking lot after a Phase 3 trial location of Johnson & Johnson's Janssen (COVID-19) vaccine candidate was announced in National City during the outbreak of the coronavirus disease (COVID-19) in National City, California, U.S., October 13, 2020. REUTERS/Mike Blake(REUTERS)

Covid-19 vaccine update: India to immunise 250 million citizens, US vaccinations might begin in December

By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 23, 2020 01:42 PM IST
The United Kingdom could give approval to Pfizer’s vaccine candidate this week, a report claimed. Meanwhile, the official Twitter account of Russia’s vaccine candidate Sputnik V claimed the price per dose of the vaccine would be “much lower” than that of Moderna and Pfizer’s vaccine candidates.
Close
Vials with a sticker reading, "Covid-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Pfizer logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic
Vials with a sticker reading, "Covid-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Pfizer logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic

Covid-19 vaccine updates: Bharat Biotech to recruit volunteers for trial, Pfizer files for emergency use authorisation

By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 21, 2020 08:13 AM IST
Britain’s AstraZeneca has launched phase three trials of an antibody combination drug, called AZD7442, that it hopes could be used to protect those at risk of contracting the coronavirus disease for up to 12 months.
Close
Haryana health minister Anil Vij (ANI)
Haryana health minister Anil Vij (ANI)

Haryana health minister Anil Vij takes trial shot of Bharat Biotech’s Covid-19 vaccine

By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 20, 2020 06:48 PM IST
Vij, who also holds the state home portfolio, had volunteered to be the first candidate for the trial shot of Covaxin. Bharat Biotech has started conducting phase 3 trials of the vaccine candidate.
Close
FILE PHOTO: Small bottles labeled with "Vaccine" stickers stand near a medical syringe in front of displayed "Coronavirus Covid-19" words in this illustration taken April 10, 2020 (REUTERS/Dado Ruvic/Illustration/File Photo)
FILE PHOTO: Small bottles labeled with "Vaccine" stickers stand near a medical syringe in front of displayed "Coronavirus Covid-19" words in this illustration taken April 10, 2020 (REUTERS/Dado Ruvic/Illustration/File Photo)

Covid-19 vaccine update: Covaxin phase 3 trials to begin in Haryana today, minister to take shot

By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 20, 2020 08:27 AM IST
Adar Poonawalla, the chief executive of Serum Institute of India, said his company may sell Covishield, the Covid-19 vaccine being developed by Oxford University, for around Rs 500-600 per shot.
Close
For the Phase 2 trial, Bharat Biotech had recruited 400 participants, and for its phase 1 trial 375 participants were recruited.(Reuters)
For the Phase 2 trial, Bharat Biotech had recruited 400 participants, and for its phase 1 trial 375 participants were recruited.(Reuters)

Bharat Biotech vaccine trial results out soon

By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON NOV 20, 2020 08:08 AM IST
The company recently announced that it had started phase 3 trials for its vaccine candidate which is India’s first vaccine candidate against Covid-19.
Close
The Indian Council of Medical Research (ICMR) is also involved in the phase 3 testing of the two vaccine candidates.(AFP)
The Indian Council of Medical Research (ICMR) is also involved in the phase 3 testing of the two vaccine candidates.(AFP)

Two out of five Covid-19 vaccines in Phase 3 trial stage: Govt

By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON NOV 18, 2020 06:32 AM IST
The two include the widely watched Oxford-AstraZeneca vaccine being tested by Serum Institute of India and the domestically developed candidate by Bharat Biotech.
Close
FILE PHOTO: A man rides his motorcycle past a parked bus of Bharat Biotech outside its office in Hyderabad (REUTERS/Stringer/File Photo)
FILE PHOTO: A man rides his motorcycle past a parked bus of Bharat Biotech outside its office in Hyderabad (REUTERS/Stringer/File Photo)

Covid-19 vaccine update: Bharat Biotech begins phase 3 trials, Moderna says its candidate nearly 95% effective

By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 17, 2020 08:57 AM IST
Meanwhile, Johnson and Johnson has launched a second phase 3 trial, besides its existing one. Also, India is reportedly in talks with several firms over their respective coronavirus vaccine candidates with regards to the progress of trials, vaccine efficacy, safety etc.
Close
The trial has been registered with the clinical trials registry of India, and approved by the Drugs Controller General of India (DCGI).(Reuters file photo. Representative image)
The trial has been registered with the clinical trials registry of India, and approved by the Drugs Controller General of India (DCGI).(Reuters file photo. Representative image)

Covid-19: Bharat Biotech begins Phase 3 trials of Covaxin in India

By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON NOV 17, 2020 06:10 AM IST
The trial will be conducted in partnership with the Indian Council of Medical Research (ICMR), the Hyderabad-based drugmaker said in a statement.
Close
A woman holds a small bottle labeled with a "Coronavirus Covid-19 Vaccine" sticker and a medical syringe in this illustration taken, October 30, 2020 (REUTERS/Dado Ruvic/File Photo)
A woman holds a small bottle labeled with a "Coronavirus Covid-19 Vaccine" sticker and a medical syringe in this illustration taken, October 30, 2020 (REUTERS/Dado Ruvic/File Photo)

Covid-19 vaccine update: Bharat Biotech candidate launch and AstraZeneca’s hopes

By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 06, 2020 06:43 PM IST
Hungary has said it will import small doses of Russian-made Sputnik V for late stage trials, by December. Meanwhile, Australia has agreed to buy 50 million more doses of two more vaccine candidates.
Close
Vials with a sticker reading, "Covid-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed AstraZeneca logo in this illustration taken October 31, 2020 (REUTERS/Dado Ruvic/Illustration)
Vials with a sticker reading, "Covid-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed AstraZeneca logo in this illustration taken October 31, 2020 (REUTERS/Dado Ruvic/Illustration)

Covid-19 vaccine update: Bharat Biotech to launch candidate in Q2 2021, Israel starts human trials

By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 02, 2020 08:17 AM IST
AstraZeneca, meanwhile, has said Britain’s health regulator has started an ‘accelerated’ review. Its vaccine candidate is called ‘AZD1222’ and is being developed in partnership with the University of Oxford.
Close
It said its immediate focus is to conduct the Phase 3 trials successfully across sites in the country.(AP)
It said its immediate focus is to conduct the Phase 3 trials successfully across sites in the country.(AP)

Bharat Biotech to launch Covaxin in Q2 2021

By Press Trust of India| Posted by Susmita Pakrasi | Hindustan Times, New Delhi
PUBLISHED ON NOV 01, 2020 11:27 AM IST
The company’s vaccine candidate -Covaxin- has been developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV) using inactivated Sars-Cov-2, the virus that causes Covid-19. The virus was isolated in an ICMR lab.
Close
Human clinical trials for Covaxin began across India in July 2020. As per the current plan, the Phase 3 trial, to determine vaccine efficacy, will begin early to mid-November this year.(Representational Photo/AP)
Human clinical trials for Covaxin began across India in July 2020. As per the current plan, the Phase 3 trial, to determine vaccine efficacy, will begin early to mid-November this year.(Representational Photo/AP)

Bharat Biotech to submit revised Phase 3 clinical trial protocol to DCGI by next week

By Rhythma Kaul | Hindustan Times,New Delhi
UPDATED ON OCT 24, 2020 08:31 AM IST
Covaxin is India’s first vaccine candidate against Covid-19
Close
:A healthcare worker is seen during swab test of the people in Chembur in Mumbai.(Pratik Chorge/HT Photo)
:A healthcare worker is seen during swab test of the people in Chembur in Mumbai.(Pratik Chorge/HT Photo)

Bharat Biotech’s Covid-19 vaccine gets nod for Phase 3 trial. Here’s how it came through

By hindustantimes.com | Edited by Meenakshi Ray | Hindustan Times, New Delhi
UPDATED ON OCT 23, 2020 10:02 PM IST
A subject expert committee on Covid-19 had recommended granting permission to Bharat Biotech for conducting latest phase of the clinical trial of its vaccine ‘Covaxin’ after assessing the safety and immunogenicity data of Phase 1 and Phase 2 trials.
Close
India’s Zydus Cadila is currently conducting mid-stage trials of its own vaccine hopeful, while Serum Institute is making potential vaccines from AstraZeneca, Novavax and Codagenix Inc, as well as developing its own.(Reuters file photo. Representative image)
India’s Zydus Cadila is currently conducting mid-stage trials of its own vaccine hopeful, while Serum Institute is making potential vaccines from AstraZeneca, Novavax and Codagenix Inc, as well as developing its own.(Reuters file photo. Representative image)

Covid-19: Bharat Biotech in talks to take vaccine candidate global

By Reuters| Posted by: Harshit Sabarwal | Bengaluru
UPDATED ON OCT 23, 2020 08:41 PM IST
The company, based in Hyderabad, this week received initial approval from Indian authorities to conduct late-stage trials for its vaccine candidate, COVAXIN.
Close
SHARE
  • 1
  • 2
  • 3
  • ...
Story Saved